Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period

• Status: Completed
• Trial end date: 2014-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the SEPLUS study is to evaluate the patients characteristics associated with adherence to Betaferon over a 24-month follow up period after the initiation of Betaferon in the BetaPlus program

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Interferon beta-1b; Interferon-beta; Interferons

Criteria

Inclusion Criteria:

• Male or female >/= 18 years old

• Outpatient with a confirmed diagnosis of Recurrent-Remittent multiple sclerosis or patients at high risk of developing multiple sclerosis after a first demyelinating clinical event

• Patient who initiated Betaferon as described by SmPC less than 2 months ago. The decision of physician is clearly separated from the decision to include the patient in the study

• Treatment naïve patients before the initiation of Betaferon

• OR Patients having interrupted Betaferon for more than 6 months before to start again

• OR Patients receiving a disease modifying drug (DMD) other than Betaferon

• Patient with EDSS score < 4

• Patients approved and signed an inform consent and approved the collect of their data

Exclusion Criteria:

• Contraindications and warning of the respective Summary of Product Characteristics